Therapeutic Advances in Myocardial Bioenergetic Modulation

Abstract

Myocardial bioenergetics, a cornerstone of cardiac physiology, underpins the heart's continual high-energy demand. In heart failure and ischemic heart disease, impaired energy production and substrate utilization contribute to disease progression and adverse outcomes. This review synthesizes current evidence regarding the epidemiology, pathophysiology, and clinical presentation of myocardial bioenergetic dysfunction, evaluates established and novel diagnostic approaches, and examines traditional and emerging therapeutic strategies aimed at restoring cardiac energetic balance. Recent advances, including metabolic modulators and mitochondrial-targeted agents, are highlighted alongside guideline-based recommendations, offering clinicians an updated perspective on practical management and future directions in the field.

Introduction

The heart's relentless contractile activity is sustained by finely tuned bioenergetic processes. Myocardial cells primarily rely on oxidative phosphorylation within mitochondria to generate adenosine triphosphate (ATP), essential for contractile function, ion homeostasis, and cellular viability. Disruption of myocardial energy metabolism is a critical pathophysiological mechanism in a spectrum of cardiac disorders, most notably heart failure and ischemic heart disease. Traditional management has focused on hemodynamic and neurohormonal modulation; however, recent research has shifted toward therapeutic strategies targeting myocardial bioenergetics, with the goal of improving both cellular function and clinical outcomes. This review provides an in-depth exploration of the clinical and mechanistic landscape of myocardial bioenergetic modulation, integrating evidence-based advances and expert recommendations for contemporary practice.

Epidemiology / Disease Burden

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, with heart failure affecting over 64 million individuals globally. Myocardial bioenergetic impairment is an almost universal feature in advanced heart failure and is also evident in earlier disease stages, contributing to disease progression, reduced functional capacity, and increased hospitalization risk. The burden is amplified in populations with comorbidities such as diabetes, obesity, and chronic kidney disease, which further exacerbate energetic deficits. Given the aging population and rising prevalence of metabolic syndrome, the clinical impact of bioenergetic dysfunction is poised to increase, underscoring the need for targeted therapeutic strategies.

Pathophysiology

Under physiological conditions, the myocardium predominantly oxidizes fatty acids (60-70%) and glucose (30-40%) to meet its energy requirements, with flexibility to adapt substrate preference based on metabolic demand and oxygen availability. In heart failure and ischemia, mitochondrial dysfunction, decreased oxidative phosphorylation, impaired substrate utilization, and increased oxidative stress collectively impair ATP production. This energetic deficit leads to contractile dysfunction, altered calcium handling, and cell death pathways activation. Additionally, maladaptive metabolic remodeling such as increased reliance on less efficient glucose metabolism or ketone bodies may initially be compensatory but ultimately contributes to progressive dysfunction.

Risk Factors

Key risk factors for myocardial bioenergetic impairment include traditional cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, obesity), advancing age, sedentary lifestyle, and genetic predisposition affecting mitochondrial function or enzymatic pathways of substrate metabolism. Comorbidities such as chronic kidney disease and chronic inflammatory states also contribute. Moreover, certain medications (e.g., some chemotherapeutic agents) and environmental toxins can induce mitochondrial toxicity, further compromising myocardial energetics.

Clinical Features

Clinically, myocardial bioenergetic dysfunction manifests as symptoms and signs of heart failure dyspnea, fatigue, exercise intolerance, and reduced ejection fraction. Subclinical forms may present as reduced myocardial contractile reserve or arrhythmias. Importantly, energetic deficits often precede overt structural changes, offering a potential window for early intervention. In ischemic heart disease, acute energetic failure contributes to stunning and hibernation, whereas chronic impairment accelerates adverse remodeling.

Diagnosis

Diagnosis of myocardial bioenergetic dysfunction is challenging due to the lack of direct clinical biomarkers. Advanced imaging modalities, such as 31-phosphorus magnetic resonance spectroscopy (31P-MRS), enable non-invasive assessment of myocardial high-energy phosphates (e.g., phosphocreatine/ATP ratio). Positron emission tomography (PET) with metabolic tracers evaluates substrate utilization patterns. Routine echocardiography and cardiac magnetic resonance imaging (MRI) assess contractile function and tissue characterization but do not directly quantify energetic status. Research is ongoing to identify circulating biomarkers of mitochondrial function and oxidative stress for clinical application.

Treatment & Management

Conventional management of heart failure and ischemic heart disease includes neurohormonal antagonists (ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors) and device therapy, which indirectly improve myocardial energetics by reducing workload and adverse remodeling. Direct metabolic modulation has recently garnered attention. Agents such as trimetazidine and ranolazine shift substrate utilization from fatty acid to glucose oxidation, improving ATP yield per oxygen molecule, particularly under ischemic conditions. Carnitine supplementation and coenzyme Q10 have shown mixed results in augmenting mitochondrial function. Optimizing comorbidities (e.g., glycemic control in diabetes) is essential to mitigate further energetic compromise.

Recent Advances / Emerging Therapies

Recent advances in myocardial bioenergetic modulation include pharmacological agents targeting mitochondrial dynamics, biogenesis, and function. Peroxisome proliferator-activated receptor (PPAR) agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors exert beneficial metabolic effects, with emerging evidence supporting improved cardiac energetics and outcomes. Novel agents such as elamipretide (a mitochondrial-targeted peptide) and agents augmenting pyruvate dehydrogenase activity show promise in early clinical trials. Ketone body supplementation is under investigation as an alternative energy source in heart failure, with preliminary studies suggesting improved cardiac efficiency and function. Non-pharmacological interventions, including structured exercise programs, have demonstrated enhancement of mitochondrial capacity and bioenergetic health.

Guideline Recommendations

Major cardiology societies (AHA/ACC, ESC) currently recommend guideline-directed heart failure therapies as first-line treatment, with metabolic modulators considered in refractory angina or selected heart failure cases. There is increasing recognition of the importance of metabolic health optimization in comprehensive cardiac care. Ongoing clinical trials may inform future guidelines regarding the routine use of mitochondrial-targeted therapies and metabolic modulators. Clinicians are encouraged to individualize therapy based on comorbidity burden, functional status, and evolving evidence.

Conclusion

Myocardial bioenergetic dysfunction is a pivotal driver of heart failure and ischemic heart disease progression. Advances in mechanistic understanding have paved the way for targeted therapeutic interventions, ranging from established metabolic modulators to novel mitochondrial-targeted agents. While guideline-directed medical therapy remains foundational, integration of bioenergetic strategies holds promise for improved patient outcomes. Continued translational and clinical research is essential to refine these approaches and expand the therapeutic arsenal available to clinicians managing complex cardiac disease.